Background/Aims: Prognostic value of neutrophil-to-lymphocyte ratio (NLR) and platelet count (PC) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC epithelial ovarian cancer (EOC) is controversial. Methods: A total of 370 stage IIIC EOC patients who underwent primary debulking surgery (PDS) at the Department of Gynecology of Liaoning Cancer Hospital and Institute between January 2003 and August 2016 and had full information were involved. Patients were stratified into a high NLR (H-NLR) group versus a low NLR (L-NLR) group and a high PC (H-PC) group versus a low PC (L-PC) group according to cutoff values calculated through receiver operating characteristic (ROC) curves. Prognostic values of NLR and PC for progression-free survival (PFS) and overall survival (OS) were assessed. Results: We identified the optimal cut-off value of 3.08 for NLR and 289.5*10 9 /L for PC. The median PFS and OS of the patients with H-NLR were shorter than L-NLR (PFS: 16.9 months vs. 19.5 months, hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.03-1.63, P = 0.022; OS: 33.5 months vs. 46.8 months, HR 1.3, 95% CI 1.01-1.66, P = 0.001). The median PFS and OS of the patients with H-PC were shorter than L-PC (PFS: 15.3 months vs. 21.6 months, HR 1.3, 95% CI 1.04-1.63, P < 0.001; OS: 37.3 months vs. 46.1 months, HR 1.14, 95% CI 0.89-1.46, P = 0.306). Conclusions: H-NLR and H-PC could predict poor long-term outcome of patients with FIGO stage III EOC.
Introduction
Epithelial ovarian cancer (EOC) has a poor prognosis. There were 22, 440 estimated new cases and 14, 080 deaths in the United States in 2017 [1] and 52, 100 estimated new cases and 22, 500 deaths in China in 2015 [2] . Even though optimal primary debulking surgery (PDS) and carboplatin-based chemotherapy have improved survival, the 5-year overall survival rate of FIGO stage III ovarian cancer (OC) is 24.26% [3] . Specific and effective biomarkers for predicting the treatment outcome of advanced EOC are urgently needed.
Tumor-associated neutrophils and thrombocytosis have been demonstrated to play important roles in tumor progression, angiogenesis, and invasion of EOC [4] . Increased neutrophil to lymphocyte ratio (NLR) and platelet count (PC) are associated with the disease severity and poor prognosis of several kinds of malignant tumor [5] [6] [7] [8] . Two meta-analyses about the prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer were published in 2017 [9, 10] . The results showed the high NLR (H-NLR) were associated with unfavorable overall survival (OS) and progression-free survival (PFS). But extreme heterogeneity existed among studies (heterogeneity of OS: I 2 80.2%, P < 0.001; heterogeneity of PFS: I 2 85.2%, P < 0.001). The subgroup analyses of both two meta-analyses according to ethnicity showed that H-NLR was associated with shorter OS for Asian patients but not Caucasian patients. Furthermore, difference of incidence and mortality of cancer existed between the patients in North and South China [2] . And the characteristics of ovarian cancer patients between North and South China were not consistent [11] . In Chen's meta-analysis, there were five Chinese studies and all of them were sponsored by the institutes in South China. In Zhou's meta-analysis, there were six Chinese studies. Among these six studies, five studies were sponsored by the institutes in South China. Only one study was sponsored by an institute in North China. And only 80 patients with FIGO stage III-IV ovarian cancer were included this retrospective study [12] . So the correlation between NLR and the prognosis of FIGO stage IIIC EOC patients in Northeast China needed further investigation.
Materials and Methods

Clinical Data
This retrospective study was approved by the ethics committees of Liaoning Cancer Hospital and Institute (Cancer Hospital of China Medical University). Written informed consent was obtained from each patient included in this study.
A total of 370 patients with FIGO stage IIIC EOC who underwent primary debulking surgery (PDS) were retrospectively investigated between January 2003 and August 2016 at the Department of Gynecology of Liaoning Cancer Hospital and Institute. All enrolled patients met the following criteria: (1) diagnosis of FIGO stage IIIC EOC; (2) performance of PDS without neoadjuvant chemotherapy; (3) suspicion of intra-abdominal diffuse disease based on preoperative radiological assessments (computed tomography/ ultrasonography); (4) use of platinum-based chemotherapy as postoperative adjuvant chemotherapy; (5) availability of data including neutrophil count, lymphocyte count, and PC; and (6) availability of other data including age, preoperative serum CA125 concentration, volume of ascites, histology and grade of tumor, Gynecologic Oncology Group performance status, and maximum size of residual disease. The 2014 FIGO guidelines removed patients with only positive retroperitoneal lymph nodes from the definition of stage IIIC EOC [13] . Therefore, we reassessed the cancer stage for all patients before 2014 according to their pathological reports. NCCN guideline was followed during the diagnosis and treatment of patients. All patients were followed up until April 30, 2017.
Optimal PDS was defined as residual disease (RD) ≤1 cm, and suboptimal PDS was defined as RD >1 cm. PFS was defined as the time interval from the date of PDS to the date of disease progression or recurrence. OS was defined as the time interval from the date of PDS to the date of death or the last follow-up.
NLR was defined as neutrophil count divided by lymphocyte count. PC was defined as the absolute value of platelet count. Preoperative peripheral blood samples from the patient were drawn within 5 days prior to surgery.
Statistical Analyses
The optimal cut-off values of NLR and PC for predicting OS were calculated through receiver operating characteristic (ROC) curves. A total of 370 patients were stratified as H-NLR group versus low NLR (L-NLR) group and as high PC (H-PC) group versus low PC (L-PC) group according to cut-off values. H-NLR and H-PC were each assigned a score of 1, and peripheral blood index value (PBIV) was defined as the total score according to the status of NLR and PC. The optimal cut-off value of PBIV predicting OS was calculated through ROC curves. The categorical data were compared with chi-square tests. PFS and OS were analyzed using the Kaplan-Meier method. Univariate analyses were performed using log-rank tests. Multivariate analyses were performed using Cox regression analysis to assess the effects of the prognostic factors, which were expressed as hazard ratios. P < 0.05 was considered statistically significant, and all P values were two-sided. Some factors, such as pre-operative ascites volume, belonged to multiple categorical variables. When <1000ml group was considered as the reference group, two dummy variables associated with 1000-3000ml and >3000ml groups, respectively, were included in the COX model. Hence, the hazard ratios were estimated between the pairs of the groups [14] . All data analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL).
Results
Cut-off values of NLR and PC
A total of 370 patients with stage FIGO III EOC were finally included in our retrospective study according to the inclusion criteria. Table 1 shows the characteristics of the patients. In 238 patients with serous carcinoma, 16 patients had low grade serous carcinoma and the other 222 patients had high grade serous carcinoma.
The following optimal cut-off values were identified: 3.08 for NLR (area under curve [AUC] 0.66, P < 0.001, sensitivity 0.62, specificity 0.65) and 289.5*10 9 /L for PC (AUC 0.61, P < 0.001, sensitivity 0.52, specificity 0.67) (Fig. 1) . Therefore, H-NLR referred to patients with NLR > 3.08 and H-PC referred to patients with PC > 289.5*10 9 /L.
Correlation between NLR and PC and clinicopathological variables
The associations between NLR and PC and the main clinicopathological variables of patients with FIGO stage IIIC EOC were investigated ( Table 2 ). H-NLR was observed more often in younger patients (P = 0.034), patients with more preoperative ascites (P < 0.001), higher preoperative CA125 value (P = 0.004), lower differentiation of tumor (P = 0.009), longer period of stay in hospital (P = 0.012), patients had blood transfusion (P = 0.001), and patients had plasma transfusion (P < 0.001). H-PC was more often observed in patients with more preoperative ascites (P < 0.001) and those with higher preoperative CA125 value (P = 0.001).
NLR and PC and survival analysis PFS and OS according to the main clinicopathological variables, NLR, and PC are shown in Table 3 .
Regarding PFS, from univariate analysis the variables associated with a shorter PFS included menopause status, volume of preoperative ascites, histology of tumor, grade of tumor, Table 3 ).
Regarding OS, from univariate analysis the variables associated with a shorter OS included histology of tumor, grade of tumor, RD, blood transfusion, regimen and cycles of adjuvant chemotherapy, second debulking surgery, NLR, and PC. Multivariate analysis by Cox regression showed that the independent variables associated with a shorter OS were histology of tumor, grade of tumor, RD, cycle of adjuvant chemotherapy and NLR. Patients with serous carcinoma mucinous had shorter OS than endometriod carcinoma but longer OS than mucinous carcinoma. Patients with ≥6 cycles of adjuvant chemotherapy had longer OS that <6 cycles. Patients with poor differentiation of tumor, RD >1 cm, and NLR >3.08 had shorter OS. The median OS of patients with NLR >3.08 was 13.3 months shorter /L was shorter than that of patients with PC<289.5*10 9 /L, but the difference was not significant (37.3 months vs. 46.1 months, HR 1.14, 95% CI 0.89-1.46, P = 0.306) (Fig. 2 and Table 3) .
Peripheral blood index value by combined NLR and PC
The PBIV of each patient was calculated. The optimal cut-off value of PBIV predicting OS was 0.5 (AUC 0.66, P < 0.001, sensitivity 0.38, specificity 0.87) (Fig. 3A) .
The median PFS of patients with PBIV >0.5 was 7.9 months shorter than that of patients with PBIV <0.5 (16.2 months vs. 24.1 months, P = 0.002) (Fig. 3B) . The median OS of patients with PBIV >0.5 was 14.0 months shorter than that of patients with PBIV <0.5 (37.3 months vs. 51.3 months, P = 0.011) (Fig. 3C) . 
Subgroup analyses for serous and non-serous EOC patients
For serous EOC patients, the median PFS of patients with NLR >3.08 was 6.7 months shorter than that of patients with NLR <3.08 (15.6 months vs. 22.3 months, P = 0.001) (Fig. 4A) . The median OS of patients with NLR >3.08 was 13.7 months shorter than that of patients with NLR <3.08 (34.9 months vs. 48.6 months, P = 0.002) (Fig. 4B) . The median PFS of patients with PC >289.5*10 9 /L was 2.2 months shorter than that of patients with PC <289.5*10 9 /L, but the difference was not significant (17.9 months vs. 20.1 months, P = 0.156) (Fig. 4C) . The median OS of patients with PC >289.5*10 9 /L was 9.5 months shorter than that of patients with PC <289.5*10 9 /L, but the difference was not significant (38.2 months vs. 47.7 months, P = 0.126) (Fig. 4D) .
For non-serous EOC patients, the median PFS of patients with NLR >3.08 was 5.4 months shorter than that of patients with NLR <3.08 (14.9 months vs. 20.3 months, P = 0.045) (Fig. 5A ). The median OS of patients with NLR >3.08 was 11.7 months shorter than that of patients with NLR <3.08, but the difference was not significant (33.5 months vs. 45.2 months, P = 0.154) (Fig. 5B) . The median PFS of patients with PC >289.5*10 9 /L was 1.9 months shorter than that of patients with PC <289.5*10 9 /L (15.8 months vs. 17.7 months, P = 0.048) (Fig. 5C ). The median OS of patients with PC >289.5*10 9 /L was 6.1 months shorter than that of patients with PC <289.5*10 9 /L, but the difference was not significant (36.8 months vs. 42.9 months, P = 0.390) (Fig. 5D ).
Discussion and Conclusion
The results of our retrospective study suggested that H-NLR and H-PC could predict poor long-term outcome of patients with FIGO stage III EOC who live in Northeast China. The median PFS and OS of the patients with H-NLR and H-PC were significantly shorter than those of patients with L-NLR and L-PC. We identified the optimal cut-off values of 3.08 for NLR and 289.5*10 9 /L for PC.
Moreover, H-NLR was associated with earlier onset age, more preoperative ascites, higher preoperative CA125 value, lower differentiation of tumor, and longer period of [18] [19] [20] [21] [22] . Most studies included only about 100 patients. Compared with these studies, we specifically analyzed the data of FIGO stage IIIC EOC patients, which avoided heterogeneity caused by tumor stage. Moreover, among these six studies, five studies were sponsored by the institutes in South China [18] [19] [20] [21] [22] . Only one retrospective study analyzing the data of 80 FIGO stage III-IV ovarian cancer patients was sponsored by an institute in North China [12] . The results suggested that H-NLR was associated with poor prognosis. Our study is the first to provide data for patients from Northeast China with advanced EOC. Other published studies analyzing the data of foreign patients outside China had the consistent conclusion with us [4, 15, 16, [23] [24] [25] .
Patients with H-PC were characterized as having thrombocytosis. H-PC was correlated with the OS of TNM stage IV colorectal cancer [26] . Watrowski R, et al. retrospectively analyzed 172 malignant and 584 benign primary adnexal tumors and indicated that H-PC predicted malignancy [27] . Several papers suggested that thrombocytosis was associated with poor prognosis of EOC patients, which was the logical consequence of the role of platelets in the pathogenesis of ovarian cancer [28] [29] [30] [31] [32] . However, the number of patients involved in the published papers was insufficient. Moreover, subgroup analysis of advanced EOC patients was limited. Our study was the first to investigate the relationship between H-PC and prognosis for the patients from Northeast China with advanced EOC.
Tumor-associated neutrophils have been demonstrated in the cancer microenvironment. Neutrophils play important roles in tumor progression, angiogenesis, and invasion [33] , and a lack of tumor-infiltrating lymphocytes is associated with poor prognosis of ovarian cancer [34, 35] . These results further support our finding that EOC patients with H-NLR had poor long-term outcome.
Our study had some strengths. First, all 370 patients involved were diagnosed with FIGO stage IIIC EOC, which eliminated bias due to stage. Second, the median follow-up period of this study exceeded 10 years. Third, NLR and PC are both easily available biomarkers. Moreover, PC is a better variable than platelet-to-lymphocyte ratio as it eliminates bias due to different lymphocyte counts. However, this study still has some limitations. As this was a mono-institutional study, a multi-institutional study investigating the predictive effect of NLR and PC in advanced EOC is needed. Moreover, this retrospective study depended on accurate documentation and a prospective study without recall bias should be performed.
In conclusion, H-NLR and H-PC could predict poor long-term outcome of patients with FIGO stage III EOC. 
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